FindTrial
Sign In

Baricitinib 4 MG

DRUG9 trials

Sponsors

University Hospital, Rouen, Assiut University, Vanderbilt University Medical Center, Nantes University Hospital, Chinese University of Hong Kong

Conditions

Active Non-anterior Non-infectious UveitisAtopic DermatitisHospital-acquired PneumoniaLupus or SLENephritisPost-Acute COVID-19 SyndromeRheumatoid ArthritisSpontaneous Subarachnoid Hemorrhage

Phase 2

Use of Baricitenib to Maintain of Remission
NCT05686746
Assiut UniversityLupus or SLE, Nephritis
Start: 2022-06-01End: 2023-08-01Target: 80Updated: 2023-01-17
Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.
NCT05914584
Nantes University HospitalHospital-acquired Pneumonia
Start: 2023-07-01End: 2025-12-31Target: 450Updated: 2023-06-22
Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
RecruitingNCT06065046
Tang-Du HospitalTraumatic Brain Injury
Start: 2023-11-24End: 2026-12-31Target: 100Updated: 2025-06-04
Baricitinib for the Lung Injury Following Spontaneous SAH
Not yet recruitingNCT06439615
Tang-Du HospitalSpontaneous Subarachnoid Hemorrhage
Start: 2024-08-01End: 2027-06-30Target: 100Updated: 2024-06-03
Baricitinib for Refractory Takayasu Arteritis
CompletedNCT06662721
Liu TianTakayasu Arteritis
Start: 2023-04-03End: 2024-06-08Updated: 2024-10-29

Phase 3

Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis
Not yet recruitingNCT05651880
University Hospital, RouenActive Non-anterior Non-infectious Uveitis
Start: 2026-03-01End: 2029-08-01Target: 33Updated: 2026-02-10
REVERSE-Long COVID-19 With Baricitinib Study
WithdrawnNCT05858515
Vanderbilt University Medical CenterPost-Acute COVID-19 Syndrome
Start: 2024-10-21End: 2029-12-30Updated: 2025-01-31

Phase 4

Effect of JAK Inhibitor on Erosion Healing in RA
RecruitingNCT05955066
Chinese University of Hong KongRheumatoid Arthritis
Start: 2023-12-01End: 2026-06-30Target: 60Updated: 2025-12-04

Unknown Phase

Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis
CompletedNCT05969730
Mazandaran University of Medical SciencesAtopic Dermatitis
Start: 2023-08-15End: 2025-11-14Updated: 2025-12-15

Related Papers

Efficacy and Safety of Baricitinib Versus Azathioprine Combined with Topical Corticosteroids in Patients with Moderate-to-Severe Atopic Dermatitis: A Single-Center, Randomized, Open-Label Trial.
2025-11-14
Baricitinib for Takayasu arteritis refractory to TNF-α inhibitors: a multicentre, single-arm trial.
2025-10-01